World J Gastroentero
-
World J Gastroentero · Sep 2008
Comparative StudyFecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.
To evaluate fecal calprotectin (FC) as a surrogate marker of treatment outcome of relapse of inflammatory bowel disease (IBD) and, to compare FC with fecal myeloperoxidase (MPO) and fecal eosinophil protein X (EPX). ⋯ A normalised FC level has the potential to be used as a surrogate marker for successful treatment outcome in IBD patients. However, patients with persistent elevation of FC levels need further evaluation. FC and MPO provide superior discrimination than EPX in IBD treatment outcome.